ImetelChat

Kmall reminds us of untapped potential, worth spending a few hours with this. Anyway we should be reminded by what we don’t see—scientists in the shadows:

https://pmc.ncbi.nlm.nih.gov/articles/P ... hatgpt.com

A look at the author list shows that there seems to be people and departments working on translational work. But where? Are there labs in Geron proper? Ties to academia or pharma that are in essence skunk works? A lab in Dubai (of all places?). Anyway, in this time of uncertainty and unhappy stock prices, at least Geron has some money in the bank (albeit a lot on loan) and a plan (of sorts). It would be nice at this point in investor uncertainty to share the plan! Here are some suggestions. What’s up with the oral prep?, the B cell/lymphoma studies? Pretty sure at EHA we will get some good updates. At least programs are active and, at least as presented to us, optimistic. A little hard data would help.

The Lymphoma #'s both patient and treatment wise globally are staggering. Definitely worth them revisiting if the potential is there for Imetelstat to be a player in the Lymphoma treatment landscape. -Kmall

This estimate is less than 2yrs from now: 2027

Global Non-Hodgkin Lymphoma Therapeutics Market Report 2021: Market to Reach $8.1 Billion by 2027 - ResearchAndMarkets.com
https://www.businesswire.com/news/home/ ... arkets.com

That link above isn't working......

Try this one instead......

"For instance, according to a study published by the American Society of Hematology in November 2022, approximately 779,000 new cases of Non-Hodgkin lymphoma are projected by 2040, marking a 43% increase from 2020. This growing burden of Non-Hodgkin lymphoma is anticipated to drive market growth. Additionally, the market is driven by a growing demand for cost-effective and accessible therapeutic solutions. Healthcare systems worldwide face the challenge of providing efficient oncology treatment within budget limitations. As a result, the escalating demand for treatments that offer both clinical efficacy and financial viability for patients drives further expansion in the market growth.

Non-Hodgkin lymphoma therapeutics refers to the range of medical treatments designed to manage and treat Non-Hodgkin lymphoma, a diverse group of blood cancers that originate in the lymphatic system. These therapies cover various approaches including chemotherapy, targeted therapy, radiation therapy, and stem cell transplantation."

https://www.gminsights.com/industry-ana ... ics-market

$17.5B (est; 2032) is quite the upgrade -Kmall